Billion-dollar autoimmune drug deal a ‘dream come true’ for Calgary researcher

With autoimmune diseases, the body’s own tissues are mistaken for harmful invaders and attacked

Dr. Pere Santamaria, a professor in the Department of Microbiology, Immunology and Infectious Diseases, and member of the university’s Snyder Institute for Chronic Diseases, poses in this undated handout photo. Parvis Therapeudics, the company Santamaria founded, and California-based company Genetech have reached a billion-dollar deal to develop a potential treatment for celiac disease, irritable bowel syndrome and other autoimmune diseases. THE CANADIAN PRESS/HO - University of Calgary, Riley Brandt

A University of Calgary researcher says he’s hopeful a deal worth up to $1 billion between his drug company and a U.S. biotechnology firm could one day lead to autoimmune disease treatments that don’t make patients more vulnerable to infections or cancer.

“It’s kind of a dream come true that I can play a role in this process and realize something that might perhaps help a lot of people,” said Pere Santamaria, founder of Parvus Therapeutics and a professor at the university’s Cumming School of Medicine.

Parvus announced a working and licensing agreement Thursday with California-based Genentech to develop, manufacture and commercialize a class of drugs known as Navacims to potentially treat celiac, autoimmune liver and inflammatory bowel diseases.

Parvus is to get an upfront payment from Genentech and further payments as certain milestones are reached. The companies are not disclosing precisely how the funds are to be broken down or over what time period. Parvus is also eligible to get royalty payments on sales that result from the deal.

READ MORE: Legalization sparks boom in field of marijuana research

The immune system is meant to protect the body from bacteria, viruses and cancer. But in people with autoimmune diseases, the body’s own tissues are mistaken for harmful invaders and attacked.

Current treatments work by suppressing the immune system as a whole, which makes patients less able to fight off infections and cancer.

Navacims, discovered by Santamaria and his team in 2004, use nanoparticles to switch off autoimmune attacks in a way that doesn’t compromise the body’s overall disease-fighting abilities.

Santamaria said the treatments have been tested extensively in mice with promising results. The deal with Genentech will go toward clinical trials in humans. Parvus will be responsible for initial small-scale tests. Genentech will take on subsequent studies in larger groups and, if successful, the regulatory work needed to bring the drug to market.

The companies aren’t disclosing when the trials will be done, but Santamaria said time is of the essence.

“It’ll take some time, but resources will be brought to bear so that this can be accelerated as fast as we can to get these drugs to patients in need.”

Parvus teamed up with another drug firm, Novartis, in 2017 to develop Navacims as a potential treatment for Type 1 diabetes.

Santamaria said bringing Navacims to market without the resources and know-how from larger partners would be inconceivable.

“It’s been a tough, long haul with a lot of challenges and hurdles in many aspects.”

University of Calgary president Ed McCauley said the big-ticket investment affirms how important it is to invest in fundamental research.

“It’s incredible,” he said. “The discoveries we are making are actually being mobilized to help society.”

Lauren Krugel, The Canadian Press

Like us on Facebook and follow us on Twitter

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

County of Stettler is unsure of Buffalo Lake RV Resort developers’ intentions or ownership

Leaseholders allege Buffalo Lake RV Resort development has possibly gone into foreclosure

Stettler authors continue to break new creative ground

Donna Hoopfer’s latest title, illustrated by her sister Joanne Hoopfer, was released earlier this year

PHOTOS: Flooding hits town on the afternoon of July 7th

Severe afternoon rain sent some folks out to explore in ‘creative’ ways

Stettler Town & Country Museum almost back to full hours

Some buildings are closed due to ongoing hail damage repairs

QUIZ: A celebration of dogs

These are the dog days of summer. How much do you know about dogs?

Racist slurs during Conservative leadership debate not surprising: Lewis

Racist slurs during Conservative leadership debate not surprising: Lewis

‘These kind of issues are out here’: New doc examines police violence in Calgary

‘These kind of issues are out here’: New doc examines police violence in Calgary

‘Vowed myself to silence:’ Woman says she couldn’t cope after Edmonton attack

‘Vowed myself to silence:’ Woman says she couldn’t cope after Edmonton attack

Alberta politicians swap charges of bullying, misogyny after member ejected

Alberta politicians swap charges of bullying, misogyny after member ejected

Police chiefs call for decriminalization of personal drug use

Police chiefs call for decriminalization of personal drug use

Serbia bans mass gatherings after virus lockdown protests

Serbia bans mass gatherings after virus lockdown protests

Mississippi seeing big virus outbreak in state legislature

Mississippi seeing big virus outbreak in state legislature

CDC head sticking to school-opening guides Trump criticized

CDC head sticking to school-opening guides Trump criticized

Most Read